Mesoporous core-shell silica nanoparticles with anti-fouling properties for ovarian cancer therapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Abstract Mesoporous silica nanoparticles (MSNPs) have many potential applications in biomedical fields. However, when MSNPs are exposed to plasma, protein adsorption leads to opsonization and decreases blood circulation time. A new multifunctional nanodevice based on polyethylenimine (PEI) coated core-shell Fe3O4@SiO2 MSNPs with a zwitterionic 2-methacryloyloxyethyl phosphorylcholine (MPC) surface was designed to minimize unspecific protein adhesion. Particle size measurements demonstrated an excellent non-fouling capacity in solutions containing Bovine Serum Albumin (BSA) and Fetal Bovine Serum (FBS) plasma proteins. The system was used in this study to co-deliver two different cargos: siRNA and daunorubicin. Anti-TWIST siRNA plays critical role in modulating knockdown of TWIST and sensitizing cells to chemotherapeutics such as daunorubicin for ovarian cancer therapy. The drug was released in response to externally controlled oscillating magnetic fields (OMF). siRNA (siGFP) silenced expression of green fluorescence protein (GFP) in Ovcar8 cancer cells, demonstrating the incorporation of core shell MSNPs into cells and siGFP delivery. The synergistic effect of the co-release of anti-TWIST-siRNA loaded in the PEI and daunorubicin loaded in NPs’ pores caused increased cytotoxicity in Ovcar8 of up to 50% from both zwitteronic and non-zwitteronic NPs. The system is the first example of silencing by anti-TWITS-siRNA/daunorubicin co-delivered using zwitterionic core-shell nanoparticles with low-fouling adsorption. This engineered multifunctional approach may provide therapeutic potential for the treatment of currently incurable ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933 · cited 1×
“been demonstrated, the cationic polymer PEI could facilitate nanoparticle uptake in some extent, so NPs-PEI is a control in the test [45].”
BackgroundSelf-citationImpact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake
Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M., & Kraft, M. L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.019 · Cited by 316
Cited by
Antifouling Strategies for Selective In Vitro and In Vivo Sensing
Jiang, C., Wang, G., Hein, R., Liu, N., Luo, X., & Davis, J. J. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00739 · Cited by 598
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Self-citationAdvances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update
Castillo, R. R., Lozano, D., González, B., Manzano, M., Izquierdo-Barba, I., & Vallet-Regí, M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598375 · Cited by 197
Self-citationDrug Targeting Strategies Based on Charge Dependent Uptake of Nanoparticles into Cancer Cells
Saadat, M., Zahednezhad, F., Zakeri-Milani, P., Reza Heidari, H., Shahbazi-Mojarrad, J., & Valizadeh, H. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30318 · Cited by 88
Antifouling zwitterionic pSBMA‐MSN particles for biomedical applications
Beltrán‐Osuna, Á. A., Ródenas‐Rochina, J., Gómez Ribelles, J. L., & Perilla, J. E. (2019) · Polymers for Advanced Technologies · doi:10.1002/pat.4505 · Cited by 14
Metadata
- Authors
- Sanchez-Salcedo, S., Vallet-Regí, M., Shahin, S. A., Glackin, C. A., & Zink, J. I.
- Venue
- Chemical Engineering Journal
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 340
- Pages
- 114-124
- ISSN
- 1385-8947 (ISSN-L)
- OpenAlex
- W2782355783
- Cited by
- 77
- References
- 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.